CCL5 and neoplasm: In addition, in Kaposi sarcomas D6/ACKR2 delays tumor progression through inhibition of inflammatory chemokines CCL-2, CCL-5 and CCL-3 and reduces macrophage infiltration and angiogenesis [15].